Published in JAMA on July 31, 1992
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis (2009) 6.96
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS (2010) 4.20
In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One (2010) 4.08
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One (2008) 3.45
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Sex workers and the control of sexually transmitted disease. Genitourin Med (1997) 2.54
Commentary: methods women can use that may prevent sexually transmitted disease, including HIV. Am J Public Health (1992) 2.54
Microbicides & their implications in HIV prevention. Indian J Med Res (2010) 2.36
The urgent need for a vaginal microbicide in the prevention of HIV transmission. Am J Public Health (1994) 2.03
Frequent use of lubricants for anal sex among men who have sex with men: the HIV prevention potential of a microbicidal gel. Am J Public Health (2000) 1.94
Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes. Antimicrob Agents Chemother (2000) 1.92
Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol (2008) 1.71
Commentary: the quest for women's prophylactic methods--hopes vs science. Am J Public Health (1992) 1.71
Randomised controlled trials in Africa of HIV and AIDS: descriptive study and spatial distribution. BMJ (2005) 1.68
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
HIV, heterosexual transmission, and women. JAMA (1992) 1.55
The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med (2005) 1.54
The double bind in science policy and the protection of women from HIV infection. Am J Public Health (1992) 1.47
Sulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens. Antimicrob Agents Chemother (1997) 1.46
High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex Transm Dis (2009) 1.38
State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr (2012) 1.37
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother (2006) 1.37
A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob Agents Chemother (1999) 1.35
The protective effect of condoms and nonoxynol-9 against HIV infection. Am J Public Health (1998) 1.28
HIV prevention: an update on the status of methods women can use. Am J Public Health (1993) 1.23
In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses. J Clin Microbiol (2000) 1.15
Twenty-five years of HIV: lessons for low prevalence scenarios. J Acquir Immune Defic Syndr (2009) 1.13
Sophorolipids, microbial glycolipids with anti-human immunodeficiency virus and sperm-immobilizing activities. Antimicrob Agents Chemother (2005) 1.12
Microbicides in HIV prevention. BMJ (2001) 1.12
Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. BMC Infect Dis (2010) 1.09
Ourselves, our bodies, our realities: an HIV prevention intervention for women with severe mental illness. J Urban Health (2001) 1.08
The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection. AIDS Res Hum Retroviruses (2012) 1.04
Bile salts: natural detergents for the prevention of sexually transmitted diseases. Antimicrob Agents Chemother (1999) 1.03
Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev (2010) 1.02
Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm (2013) 1.02
The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro. Antimicrob Agents Chemother (1997) 1.01
A systematic review of the quality of trials evaluating biomedical HIV prevention interventions shows that many lack power. HIV Clin Trials (2010) 0.98
Nonoxynol-9 use, genital ulcers, and HIV infection in a cohort of sex workers. Genitourin Med (1995) 0.94
Spermicides, HIV, and the vaginal sponge. JAMA (1992) 0.92
GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion. AAPS PharmSciTech (2001) 0.91
Optical coherence tomography compared with colposcopy for assessment of vaginal epithelial damage: a randomized controlled trial. Obstet Gynecol (2011) 0.91
Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases. Antimicrob Agents Chemother (2001) 0.91
Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract Res Clin Obstet Gynaecol (2012) 0.90
Microbicides for HIV prevention. Indian J Med Res (2011) 0.90
Comparative study of mechanisms of herpes simplex virus inactivation by sodium lauryl sulfate and n-lauroylsarcosine. Antimicrob Agents Chemother (2002) 0.89
Surfactants as microbicides and contraceptive agents: a systematic in vitro study. PLoS One (2008) 0.88
Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis (2012) 0.87
Use of high-resolution confocal imaging of the vaginal epithelial microstructure to detect microbicide toxicity. J Infect Dis (2009) 0.87
Spermicide acceptability among patients at a sexually transmitted disease clinic in Zambia. Am J Public Health (1995) 0.87
Community empowerment and involvement of female sex workers in targeted sexual and reproductive health interventions in Africa: a systematic review. Global Health (2014) 0.87
Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation. PLoS One (2014) 0.86
Safety and acceptability of vaginal disinfection with benzalkonium chloride in HIV infected pregnant women in west Africa: ANRS 049b phase II randomized, double blinded placebo controlled trial. DITRAME Study Group. Sex Transm Infect (1999) 0.86
Barrier methods of contraception, spermicides, and sexually transmitted diseases: a review. Genitourin Med (1994) 0.86
Methodologies for evaluating HIV prevention intervention (populations and epidemiologic settings). Curr Opin HIV AIDS (2009) 0.85
The Development of Microbicides for Clinical Use to Prevent Sexually Transmitted Diseases. Curr Infect Dis Rep (2002) 0.84
In vitro surfactant structure-toxicity relationships: implications for surfactant use in sexually transmitted infection prophylaxis and contraception. PLoS One (2011) 0.84
Loss to follow-up as a competing risk in an observational study of HIV-1 incidence. PLoS One (2013) 0.84
MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection. Antimicrob Agents Chemother (2014) 0.84
Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment. Antimicrob Agents Chemother (2001) 0.83
Increased CCL2 expression and macrophage/monocyte migration during microbicide-induced vaginal irritation. Curr HIV Res (2009) 0.83
An Update on Vaginal Microbicides. Curr Infect Dis Rep (2001) 0.83
Gynecologic issues in the HIV-infected woman. Infect Dis Clin North Am (2008) 0.83
Quantitative assessment of microbicide-induced injury in the ovine vaginal epithelium using confocal microendoscopy. BMC Infect Dis (2012) 0.82
Microbicides: a new hope for HIV prevention. Indian J Med Res (2011) 0.81
The importance of the vaginal delivery route for antiretrovirals in HIV prevention. Ther Deliv (2011) 0.81
New candidate biomarkers in the female genital tract to evaluate microbicide toxicity. PLoS One (2014) 0.81
Topical microbicides and HIV prevention in the female genital tract. J Clin Pharmacol (2014) 0.81
Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States. Infect Dis Rep (2011) 0.81
Pregnancy incidence and risk factors among women participating in vaginal microbicide trials for HIV prevention: systematic review and meta-analysis. PLoS One (2013) 0.80
Effects of long-term use of nonoxynol-9 on vaginal flora. Obstet Gynecol (2006) 0.80
Changes in sexual risk behavior in the Mombasa cohort: 1993-2007. PLoS One (2014) 0.80
Incomplete protection against simian immunodeficiency virus vaginal transmission in rhesus macaques by a topical antiviral agent revealed by repeat challenges. J Virol (2008) 0.78
New Success With Microbicides and Pre-Exposure Prophylaxis for Human Immunodeficiency Virus (HIV): Is Female-Controlled Prevention the Answer to the HIV Epidemic? Rev Obstet Gynecol (2012) 0.78
A randomized controlled trial comparing nonoxynol-9 lubricated condoms with silicone lubricated condoms for prophylaxis. Sex Transm Infect (1998) 0.76
Self-reported discomfort associated with use of different nonoxynol-9 spermicides. Genitourin Med (1996) 0.75
Changing HIV risk behaviors: the case against pessimism. Am J Public Health (1993) 0.75
Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies. BJOG (2014) 0.75
SR-2P vaginal microbicide gel provides protection against herpes simplex virus 2 when administered as a combined prophylactic and postexposure therapeutic. Antimicrob Agents Chemother (2015) 0.75
What's in a name when efficacy isn't efficacious? JAMA (1993) 0.75
Potential Use of Antimicrobial Peptides as Vaginal Spermicides/Microbicides. Pharmaceuticals (Basel) (2016) 0.75
Non-Antiretroviral Microbicides for HIV Prevention. AIDS Rev (2016) 0.75
A multiple testing procedure for clinical trials. Biometrics (1979) 26.80
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA (2000) 10.40
Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis (1991) 7.05
One-sample multiple testing procedure for phase II clinical trials. Biometrics (1982) 6.45
Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: A randomized clinical trial. JAMA (2001) 5.77
An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA (1993) 5.43
The right not to know HIV-test results. Lancet (1995) 5.16
Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial. Lancet (2001) 5.10
Criteria for selective screening for Chlamydia trachomatis infection in women attending family planning clinics. JAMA (1986) 4.93
A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med (1996) 4.69
Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med (1997) 4.64
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol (1989) 4.03
Prognosis in primary biliary cirrhosis: model for decision making. Hepatology (1989) 3.83
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg (1996) 3.76
The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA (1988) 3.73
Designs for group sequential tests. Control Clin Trials (1984) 3.56
Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest (1998) 3.53
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med (1985) 3.36
Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med (1998) 2.95
Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol (1999) 2.90
Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet (1997) 2.88
Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med (2001) 2.83
A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med (2000) 2.81
The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis (2001) 2.79
Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. Biometrics (1989) 2.51
Risk factors for recurrent urinary tract infection in young women. J Infect Dis (2000) 2.48
Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis (1989) 2.41
Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA (1993) 2.41
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Prevention of transmission of human immunodeficiency virus in Africa: effectiveness of condom promotion and health education among prostitutes. Lancet (1988) 2.33
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA (1999) 2.21
The importance of core groups in the epidemiology and control of HIV-1 infection. AIDS (1991) 2.21
Structure of RNA and RNA binding site in tobacco mosaic virus from 4-A map calculated from X-ray fibre diagrams. Nature (1977) 2.20
Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics (1995) 2.19
Transmission of epidemic Vibrio cholerae O1 in rural western Kenya associated with drinking water from Lake Victoria: an environmental reservoir for cholera? Am J Trop Med Hyg (1999) 2.19
Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol (1982) 2.12
Natural history of recurrent urinary tract infections in women. Rev Infect Dis (1991) 2.05
Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis (1997) 2.02
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
Human immunodeficiency virus infection in long-distance truck drivers in east Africa. Arch Intern Med (1994) 2.01
Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection. J Clin Invest (1989) 1.98
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Aerobactin and other virulence factor genes among strains of Escherichia coli causing urosepsis: association with patient characteristics. Infect Immun (1988) 1.93
Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. J Infect Dis (1998) 1.92
Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS (2001) 1.88
Prevalence of Mycoplasma genitalium determined by DNA probe in men with urethritis. Lancet (1988) 1.86
Lymphocyte subsets in human immunodeficiency virus type 1-infected and uninfected children in Nairobi. Pediatr Infect Dis J (2001) 1.81
Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis (2000) 1.77
Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis (1998) 1.74
Association of carboxylesterase B electrophoretic pattern with presence and expression of urovirulence factor determinants and antimicrobial resistance among strains of Escherichia coli that cause urosepsis. Infect Immun (1991) 1.73
Genotype analysis of Escherichia coli strains isolated from children and chickens living in close contact. Appl Environ Microbiol (1999) 1.73
Risk and aetiology of diarrhoea at various tourist destinations. Lancet (2000) 1.72
Intestinal spirochetosis in homosexual men. Am J Med (1987) 1.72
Escherichia coli bacteriuria and contraceptive method. JAMA (1991) 1.71
Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis (1994) 1.70
Sociodemographic distribution of gonorrhea incidence: implications for prevention and behavioral research. Am J Public Health (1991) 1.69
Obstruction after ileal pouch-anal anastomosis: a preventable complication? Dis Colon Rectum (1993) 1.62
Human immunodeficiency virus type 1-infected cells in breast milk: association with immunosuppression and vitamin A deficiency. J Infect Dis (1995) 1.62
HIV infection among lower socioeconomic strata prostitutes in Nairobi. AIDS (1990) 1.62
O, K, and H antigens predict virulence factors, carboxylesterase B pattern, antimicrobial resistance, and host compromise among Escherichia coli strains causing urosepsis. J Infect Dis (1994) 1.62
Maternal human immunodeficiency virus-1 infection and pregnancy outcome. Obstet Gynecol (1994) 1.60
Assessing fitness for surgery: a comparison of questionnaire, incremental shuttle walk, and cardiopulmonary exercise testing in general surgical patients. Br J Anaesth (2008) 1.59
Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex Transm Dis (1999) 1.58
Anal and dry sex in commercial sex work, and relation to risk for sexually transmitted infections and HIV in Meru, Kenya. Sex Transm Infect (2006) 1.53
Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol (1993) 1.52
Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J Infect Dis (1998) 1.51
Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology (1992) 1.51
Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis (2001) 1.50
Evaluation of a new cephalosporin antibiotic, cephapirin. Antimicrob Agents Chemother (1972) 1.50
Urinary tract infections: from pathogenesis to treatment. J Infect Dis (1989) 1.50
No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res Hum Retroviruses (2005) 1.47
A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med (1982) 1.47
Preparation for AIDS vaccine evaluation in Mombasa, Kenya: establishment of seronegative cohorts of commercial sex workers and trucking company employees. AIDS Res Hum Retroviruses (1994) 1.47
Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis (1993) 1.47
Implementing and evaluating a system of generic infection precautions: body substance isolation. Am J Infect Control (1990) 1.45
P fimbriae and other virulence factors in Escherichia coli urosepsis: association with patients' characteristics. J Infect Dis (1987) 1.43
Policies for study monitoring and interim reporting of results. J Clin Oncol (1987) 1.41
Value of virus filtration as a method for improving the safety of plasma products. Vox Sang (1995) 1.39
How often do patients return to the operating room after colorectal resections? Colorectal Dis (2012) 1.39
Antimicrobial-resistant bacterial diarrhea in rural western Kenya. J Infect Dis (2001) 1.39
In vitro evaluation of a new quinolone antibacterial. Antimicrob Agents Chemother (1975) 1.38
Severe heat treatment of freeze-dried coagulation factor concentrates: is hotter necessarily better? Vox Sang (1995) 1.37
Pulmonary resection for metastatic nonosteogenic sarcoma. Cancer (1979) 1.34
Trimethoprim-sulfamethoxazole for acute dysuria in women: a single-dose or 10-day course. A double-blind, randomized trial. Ann Intern Med (1988) 1.33
Impact of maternal HIV infection on obstetrical and early neonatal outcome. AIDS (1990) 1.32
Human immunodeficiency virus, human papillomavirus, and cervical intraepithelial neoplasia in Nairobi prostitutes. Sex Transm Dis (1992) 1.32
Detection and quantitation of cells secreting IL-6 under physiologic conditions in BALB/c mice. J Immunol (1993) 1.30
Prevalence and risk factors for sexually transmitted infections in a high-risk occupational group: the case of fishermen along Lake Victoria in Kisumu, Kenya. Int J STD AIDS (2010) 1.29
Quantitative and qualitative analysis of gastroesophageal reflux after percutaneous endoscopic gastrostomy. J Pediatr Surg (2002) 1.29